Glenmark Pharmaceuticals receives ANDA approval for Dimethyl Fumarate Delayed-Release Capsules, 120 mg and 240 mg

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Dimethyl Fumarate Delayed-Release Capsules, 120 mg and 240 mg, the generic version of Tecfidera1 Delayed-Release Capsules, 120 mg and 240 mg, of Biogen, Inc.

According to IQVIA™ sales data for the 12 month period ending August, the Tecfidera Delayed-Release Capsules, 120 mg and 240 mg market2 achieved annual sales of approximately $3.8 billion*.

Glenmark's current portfolio consists of 164 products authorized for distribution in the U.S. marketplace and 46 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Shares of GLENMARK PHARMACEUTICALS LTD. was last trading in BSE at Rs.490.25 as compared to the previous close of Rs. 496.8. The total number of shares traded during the day was 89412 in over 2415 trades.

The stock hit an intraday high of Rs. 504.65 and intraday low of 488.5. The net turnover during the day was Rs. 44254644.

1All brand names and trademarks are the property of their respective owners.
2Market includes brand and all available therapeutic equivalents
*IQVIA™ National Sales Perspectives: Retail & Non-Retail, August 2020

Source : Equity Bulls

Keywords